Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

被引:0
|
作者
Allen, Jeffrey A. [1 ]
Lin, Jie [2 ]
Basta, Ivana [3 ]
Dysgaard, Tina [4 ]
Eggers, Christian [5 ]
Guptill, Jeffrey [6 ,7 ]
Gwathmey, Kelly G. [8 ]
Hewamadduma, Channa [9 ,10 ]
Hofman, Erik [6 ]
Hussain, Yessar M. [11 ]
Kuwabara, Satoshi [12 ]
Le Masson, Gwendal [13 ]
Leypoldt, Frank [14 ,15 ]
Chang, Ting [16 ]
Lipowska, Marta [17 ,18 ]
Lowe, Murray [6 ]
Lauria, Giuseppe [19 ]
Querol, Luis [20 ,21 ]
Simu, Mihaela-Adriana [22 ]
Suresh, Niraja [23 ]
Tse, Anissa [6 ]
Ulrichts, Peter [6 ]
Van Hoorick, Benjamin [6 ]
Yamasaki, Ryo [24 ,25 ]
Lewis, Richard A. [26 ]
van Doorn, Pieter A. [27 ]
机构
[1] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA
[2] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China
[3] Univ Belgrade, Univ Clin Ctr Serbia, Fac Med, Neurol Clin, Belgrade, Serbia
[4] Univ Copenhagen, Dept Neurol, Copenhagen, Denmark
[5] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Neurol, Linz, Austria
[6] Argenx, Ghent, Belgium
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA
[9] Univ Sheffield, Sheffield Inst Translat Neurosci SITRAN, Sheffield, England
[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England
[11] Austin Neuromuscular Ctr, Austin, TX USA
[12] Chiba Univ, Grad Sch Med, Dept Neurol, Chiba, Japan
[13] Univ Hosp Bordeaux, AOC Natl Reference Ctr Neuromuscular Disorders, ALS Ctr, Dept Neurol,CHU Bordeaux,NerveMuscle Unit, Bordeaux, France
[14] Christian Albrecht Univ Kiel, Inst Clin Chem, Dept Neurol, Kiel, Germany
[15] Univ Med Ctr Schleswig Holstein, Kiel, Germany
[16] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China
[17] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[18] European Reference Network Rare Neuromuscular Dis, Paris, France
[19] IRCCS Fdn Ist Neurol Carlo Besta, Milan, Italy
[20] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona, Spain
[21] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
[22] Victor Babes Univ Med & Pharm, Dept Neurol, Timisoara, Romania
[23] Univ S Florida, Dept Neurol, Tampa, FL USA
[24] Kyushu Univ Hosp, Dept Neurol, Fukuoka, Japan
[25] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan
[26] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA USA
[27] Erasmus MC, Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands
来源
LANCET NEUROLOGY | 2024年 / 23卷 / 10期
关键词
NERVE SOCIETY GUIDELINE; MANAGEMENT; CIDP; IVIG;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives. Efgartigimod alfa, a human IgG1 antibody Fc fragment, has demonstrated efficacy and safety in patients with generalised myasthenia gravis. We evaluated the safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in adults with CIDP.<br /> Methods ADHERE, a multistage, double-blind, placebo-controlled trial, enrolled participants with CIDP from 146 clinical sites from Asia-Pacific, Europe, and North America. Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A). Those with confirmed evidence of clinical improvement (ECI; treatment responders) entered a randomised-withdrawal phase of 1000 mg subcutaneous efgartigimod PH20 weekly treatment versus placebo for a maximum of 48 weeks (stage B). Participants were randomised (1:1) through interactive response technology and stratified by their adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score change during stage A and their most recent CIDP medication within 6 months before screening. Investigators, the clinical research organisation, and participants were masked to the treatment. The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (>= 1 points aINCAT decrease, >= 4 points [centile metric] Inflammatory Raschbuilt Overall Disability Scale increase, or >= 8 kPa grip strength increase after four injections and two consecutive visits). The primary endpoint in stage B, evaluated in the modified intention-to-treat population, was the risk of relapse (time to first aINCAT increase of >= 1 points). ADHERE is registered with ClinicalTrials.gov (NCT04281472) and EudraCT (2019-003076-39) and is completed.<br /> Findings Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61<middle dot>0-71<middle dot>6) had confirmed ECI. In stage B, 221 participants were randomised (79 female, 142 male; 111 to subcutaneous efgartigimod PH20, 110 to placebo). Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0<middle dot>39 [95% CI 0<middle dot>25-0<middle dot>61]; p<0<middle dot>0001). 31 (27<middle dot>9% [19<middle dot>6-36<middle dot>3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53<middle dot>6% [44<middle dot>3-63<middle dot>0]) given placebo. In stage A, treatment-emergent adverse events (TEAEs) occurred in 204 (63%) participants and serious TEAEs in 21 (7%). In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo. Three deaths occurred: two in stage A (one non-related and one unlikely related to treatment) and one in stage B (placebo group).<br /> Interpretation ADHERE showed the efficacy of subcutaneous efgartigimod PH20 in reducing the risk of relapse versus placebo in people with CIDP who responded to treatment. Further studies are needed to provide data on the longer-term effects of efgartigimod alfa and how it compares with currently available treatment options.
引用
收藏
页码:1013 / 1024
页数:12
相关论文
共 50 条
  • [21] Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
    Riva, Nilo
    Mora, Gabriele
    Soraru, Gianni
    Lunetta, Christian
    Ferraro, Ottavia E.
    Falzone, Yuri
    Leocani, Letizia
    Fazio, Raffaella
    Comola, Mauro
    Comi, Giancarlo
    Formaglio, Fabio
    Rossi, Paolo
    Clerici, Marta
    Falzone, Yuri Matteo
    Pozzi, Laura
    Martinelli, Daniele
    Cerri, Federica
    Diego, Lopez Ignazio
    Martinelli-Boneschi, Filippo
    Quattrini, Angelo
    Pieri, Elisabetta
    Marinou, Kalliopi
    Querin, Giorgia
    Sansone, Valeria
    Maestri, Eleonora
    Calvo, Andrea
    Chio, Adriano
    LANCET NEUROLOGY, 2019, 18 (02): : 155 - 164
  • [22] Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
    Chitnis, Tanuja
    Banwell, Brenda
    Kappos, Ludwig
    Arnold, Douglas L.
    Guecueyener, Kivilcim
    Deiva, Kumaran
    Skripchenko, Natalia
    Cui, Li-Ying
    Saubadu, Stephane
    Hu, Wenruo
    Benamor, Myriam
    Le-Halpere, Annaig
    Truffinet, Philippe
    Tardieu, Marc
    LANCET NEUROLOGY, 2021, 20 (12): : 1001 - 1011
  • [23] Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial
    Szakacs, Zoltan
    Dauvilliers, Yves
    Mikhaylov, Vladimir
    Poverennova, Irina
    Krylov, Sergei
    Jankovic, Slavko
    Sonka, Karel
    Lehert, Philippe
    Lecomte, Isabelle
    Lecomte, Jeanne-Marie
    Schwartz, Jean-Charles
    LANCET NEUROLOGY, 2017, 16 (03): : 200 - 207
  • [24] Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
    Ramanan, Athimalaipet, V
    Quartier, Pierre
    Okamoto, Nami
    Foeldvari, Ivan
    Spindler, Alberto
    Fingerhutova, Sarka
    Anton, Jordi
    Wang, Zhongkai
    Meszaros, Gabriella
    Araujo, Joana
    Liao, Ran
    Keller, Stuart
    LANCET, 2023, 402 (10401): : 555 - 570
  • [25] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
    Bigal, Marcelo E.
    Edvinsson, Lars
    Rapoport, Alan M.
    Lipton, Richard B.
    Spierings, Egilius L. H.
    Diener, Hans-Christoph
    Burstein, Rami
    Loupe, Pippa S.
    Ma, Yuju
    Yang, Ronghua
    Silberstein, Stephen D.
    LANCET NEUROLOGY, 2015, 14 (11): : 1091 - 1100
  • [26] Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
    Cid, Maria C.
    Unizony, Sebastian H.
    Blockmans, Daniel
    Brouwer, Elisabeth
    Dagna, Lorenzo
    Dasgupta, Bhaskar
    Hellmich, Bernhard
    Molloy, Eamonn
    Salvarani, Carlo
    Trapnell, Bruce C.
    Warrington, Kenneth J.
    Wicks, Ian
    Samant, Manoj
    Zhou, Teresa
    Pupim, Lara
    Paolini, John F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 653 - 661
  • [27] Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
    Gulati, Anil
    Adwani, Sikandar Gokuldas
    Vijaya, Pamidimukkala
    Agrawal, Nilesh Radheshyam
    Ramakrishnan, T. C. R.
    Rai, Hari Prakash
    Jain, Dinesh
    Sundarachary, Nagarjunakonda Venkata
    Pandian, Jeyaraj Durai
    Sardana, Vijay
    Sharma, Mridul
    Sidhu, Gursaran Kaur
    Anand, Sidharth Shankar
    Vibha, Deepti
    Aralikatte, Saroja
    Khurana, Dheeraj
    Joshi, Deepika
    Karadan, Ummer
    Siddiqui, Mohd. Shafat Imam
    DRUGS, 2024, : 1637 - 1650
  • [28] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Rovin, Brad H.
    Teng, Y. K. Onno
    Ginzler, Ellen M.
    Arriens, Cristina
    Caster, Dawn J.
    Romero-Diaz, Juanita
    Gibson, Keisha
    Kaplan, Joshua
    Lisk, Laura
    Navarra, Sandra
    Parikh, Samir V.
    Randhawa, Simrat
    Solomons, Neil
    Huizinga, Robert B.
    LANCET, 2021, 397 (10289): : 2070 - 2080
  • [29] Efficacy and safety of butylphthalide in patients with mild cognitive impairment: a multicentre, randomised, double-blind, placebo-controlled trial (EBMCI study)
    Wang, Pin
    Sun, Wenxian
    Gong, Jin
    Han, Xiaodong
    Xu, Chang
    Chen, Yufei
    Yang, Yuting
    Luan, Heya
    Li, Shaoqi
    Li, Ruina
    Wen, Boye
    Lv, Sirong
    Wei, Cuibai
    BMJ OPEN, 2024, 14 (07):
  • [30] Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial
    Koch, Jan C.
    Leha, Andreas
    Bidner, Helen
    Cordts, Isabell
    Dorst, Johannes
    Gunther, Rene
    Zeller, Daniel
    Braun, Nathalie
    Metelmann, Moritz
    Corcia, Philippe
    de la Cruz, Elisa
    Weydt, Patrick
    Meyer, Thomas
    Grosskreutz, Julian
    Soriani, Marie-Helene
    Attarian, Shahram
    Weishaupt, Jochen H.
    Weyen, Ute
    Kuttler, Josua
    Zurek, Gabriela
    Rogers, Mary-Louise
    Feneberg, Emily
    Deschauer, Marcus
    Neuwirth, Christoph
    Wuu, Joanne
    Ludolph, Albert C.
    Schmidt, Jens
    Remane, Yvonne
    Camu, William
    Friede, Tim
    Benatar, Michael
    Weber, Markus
    Lingor, Paul
    LANCET NEUROLOGY, 2024, 23 (11): : 1133 - 1146